Personalized Triple Therapy Shows 87.6% Response Rate in Advanced, Refractory Cancers

Between 2017 and early 2026, seventy-three patients with advanced cancers that had stopped responding to standard treatment walked into the Salem Oncology Center in Houston. Most had been told their disease was terminal. What they received was not a single drug or a standard protocol, but something closer to a custom-built treatment designed specifically for their tumor.

The approach, called ICTriplex, combines three therapeutic weapons: chemotherapy, immune checkpoint inhibitors, and targeted therapy. But the name obscures what makes it genuinely different. Every patient received all three modalities, yet no two patients received the same combination. A woman with lung cancer might get one set of drugs; a man with pancreatic cancer, a completely different arsenal. The difference came down to biology. Before treatment began, researchers sequenced and analyzed each tumor's genetic and molecular profile. They looked at what the cancer was made of, how it had evolved, what it had already survived. Then they built a treatment plan around those findings.

The patient population was diverse and heavily burdened. Fourteen had lung cancer, thirteen colorectal, eleven pancreatic, six biliary tract, six breast, four ovarian, four sarcoma, three glioblastoma, three melanoma, three gastric, two cervical, and four others. All had exhausted conventional options or had cancers for which no standard therapy existed. The chemotherapy backbone typically consisted of taxanes, gemcitabine, or platinum agents—the workhorses of oncology. To these, researchers added checkpoint inhibitors like atezolizumab, nivolumab, or pembrolizumab, which release the immune system's brakes on cancer cells. Then came targeted therapies such as bevacizumab or erlotinib, drugs designed to hit specific molecular vulnerabilities in the tumor.

The results were striking. Across all tumor types, 47.9 percent of patients achieved complete remission—meaning no detectable cancer on PET/CT scans. Another 39.7 percent had partial remission. The overall remission rate was 87.6 percent. Lung cancer proved most responsive, with 64 percent of those patients reaching complete remission. In five lung cancer patients with brain metastases, four achieved complete remission in the brain when the disease cleared systemically; one cleared systemically but retained brain involvement. Most remarkably, four patients who had been considered terminal before treatment began were alive and disease-free five years later.

For those who achieved complete remission, the survival data was substantial. Median progression-free survival reached fifteen months. Median overall survival was forty-one months—more than three years from a point when many had been given months to live. These figures were calculated using standard Kaplan-Meier methodology and tracked rigorously at a single center, lending them credibility.

The treatment was not without cost. Three patients died from complications possibly related to the checkpoint inhibitors, though causality was not definitively established. Other side effects occurred but remained manageable and within expected ranges. The three deaths among seventy-three patients represent a real and sobering toll, though the authors note that these were patients for whom standard options had been exhausted.

What distinguishes this work is not merely the remission rates, though those are impressive for a population of heavily pretreated, refractory patients. It is the principle underlying the approach: that cancer's uniqueness demands unique treatment. The study suggests that applying a one-size-fits-all protocol to patients with molecularly distinct tumors may be leaving efficacy on the table. By tailoring therapy to each tumor's biological identity, the researchers achieved remission rates that would be considered exceptional even in treatment-naive populations.

The findings remain preliminary—this is a single-center study without a control arm, and the patient numbers are modest. But the consistency of response across diverse tumor types, and the survival outcomes in a population previously considered beyond help, suggest the approach warrants larger, more rigorous investigation. For patients with advanced cancers and no standard treatment options, ICTriplex may represent a path forward.